Merck KGaA expands life science footprint with Bio-Techne acquisition

What happened: On June 25, Germany's Merck KGaA announced a $11.3 billion acquisition of U.S.-based Bio-Techne Corp (NASDAQ:TECH), a significant deal in the pharmaceutical and life-sciences sector. Merck will pay $73 per share in cash, a 36% premium to Bio-Techne's closing price on June 24. Bio-Techne's shares surged 20.02% to close at $70.67, with a trading volume of 51 million.

Market impact: The acquisition drives expansion of Merck's life science footprint, bolstering its offerings in reagents, instruments, and bioprocessing tools. It also signals increased M&A activity in the life sciences sector, potentially triggering further consolidation among competitors. Bio-Techne's shareholders benefit from the premium offered, while Merck's shareholders await updates on the deal's impact on the company's financials.

What to watch next: Investors should monitor the deal's closing conditions and timetable. Merck's earnings report, scheduled for July 28, will provide insights into how the acquisition fits into the company's financial strategy. Additionally, any regulatory updates on the deal's approval process will be crucial in determining its progress.